首頁 > 市場調查報告書 > 醫療設備

美容整形

北美肉毒桿菌毒素市場預測至2031 年- 區域分析- 按產品（肉毒桿菌毒素A 和肉毒桿菌毒素B）、應用（醫療和美容）和最終用戶（專科和皮膚科診所、醫院和診所等）

市場調查報告書

商品編碼

1592653

北美肉毒桿菌毒素市場預測至2031 年- 區域分析- 按產品（肉毒桿菌毒素A 和肉毒桿菌毒素B）、應用（醫療和美容）和最終用戶（專科和皮膚科診所、醫院和診所等）

North America Botulinum Toxin Market Forecast to 2031 - Regional Analysis - by Product (Botulinum Toxin A and Botulinum Toxin B), Application (Medical and Aesthetic), and End User (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others)

出版日期: 2024年09月16日 | 出版商:

The Insight Partners | 英文 77 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2023年北美肉毒桿菌毒素市值為48.0129億美元，預計到2031年將達到120.726億美元；預計2023年至2031年複合年成長率為12.2%。

擴大治療應用推動北美肉毒桿菌毒素市場

A 型和 B 型肉毒桿菌毒素可阻斷神經肌肉和神經分泌接頭處釋放的囊泡乙醯膽鹼，為需要神經復健介入的患者提供強大的治療效果。根據臨床報告，肉毒桿菌毒素已被證明對頭痛、流涎和多汗症等具有治療作用。肉毒桿菌治療可以作為手術的替代方案。對於慢性肛裂患者來說，它似乎是括約肌切開術的一種有前途的替代方法。患有一些自主神經疾病（如垂涎欲滴或味覺出汗）和腺體分泌過多（患者接受腮腺手術後經常發生的情況）的患者對肉毒桿菌毒素反應良好。儘管輔助生殖技術領域取得了許多進步，但仍有相當多的患者反覆遭受著床失敗的困擾。子宮內膜的充分生長對於輔助生殖過程中的胚胎著床和懷孕持續起著至關重要的作用。多年來，肉毒桿菌毒素已廣泛應用於整形和美容手術；研究表明，肉毒桿菌毒素對人類角質形成細胞的上皮再形成和內皮細胞的血管生成有正面影響。臨床結果表明，肉毒桿菌毒素透過增加細胞增殖和血管形成，減少膠原蛋白累積病變，促進薄子宮內膜受損結構和受損功能的恢復，最終有助於胚胎成功植入。因此，肉毒桿菌治療應用的不斷擴大可能會在未來幾年帶來新的肉毒桿菌毒素市場趨勢。

北美肉毒毒素市場概況

北美肉毒桿菌毒素市場分為美國、加拿大和墨西哥。北美市場的成長主要與經濟穩定的人口以及上述國家進行的非手術或微創美容手術數量的增加有關。透過注射肉毒桿菌毒素減少臉部皺紋是美國最常進行的美容手術。對於願意將美容療程納入其實踐的臨床醫生來說，這是最常見的入門手術之一。根據國際美容整形外科學會（ISAPS）統計，2021年美國進行了近250萬例肉毒桿菌毒素手術。可預測的結果，副作用很少，病人滿意度高。 Allergan 的 BOTOX Cosmetic/Vistabel、Galderma 和 Ipsen 的 Dysport/Azzalure、Merz 的 Xeomin/Bocouture 和 Evolus 的 Jeuveau（僅由 Daewoong 為美國生產）是該國市售的肉毒毒素產品。美國 FDA 已批准 BOTOX 化妝品適用於 18-65 歲年齡層的人。據美國美容整形外科協會稱，肉毒桿菌注射是美容行業中成長最快的手術。 2023年8月，Daxxify（daxibotulinumtoxinA-lanm）被FDA核准為治療成人頸部肌張力失調的第一個治療適應症。頸部肌張力失調的特徵是頸部肌肉無法控制地發生痙攣或收縮，導致異常運動、姿勢不當、頭頸部疼痛。這種情況影響了大約 6 萬名美國人。注射肉毒桿菌毒素有利於頸部肌張力失調患者受影響的肌肉放鬆，進而減少僵硬和痙攣。然而，治療效果會慢慢消失，因此患者需要頻繁復治。此前，2021年7月，FDA批准了艾伯維公司旗下艾爾建公司BOTOX Cosmetic的標籤擴展。艾爾建 (Allergan) 擴大了 BOTOX 的應用範圍，可治療 8 種與成人上肢痙攣相關的新肌肉疾病。

北美肉毒桿菌毒素市場收入及 2031 年預測（百萬美元）

北美肉毒毒素市場細分

北美肉毒桿菌毒素市場按產品、應用、最終用戶和國家分類。

根據產品，北美肉毒桿菌毒素市場分為肉毒桿菌毒素A和肉毒桿菌毒素B。

從應用來看，北美肉毒桿菌市場分為醫療和美容。 2023年，醫療領域在北美肉毒桿菌毒素市場中佔據較大佔有率。此外，美感部分也細分為皺眉紋/眉間紋、額頭紋、魚尾紋、方下巴/咬肌等。

依最終用戶分類，北美肉毒桿菌市場分為專科和皮膚科診所、醫院和診所等。 2023 年，專科診所和皮膚科診所佔據北美肉毒桿菌市場的最大佔有率。

按國家/地區分類，北美肉毒桿菌市場分為美國、加拿大和墨西哥。 2023年，美國在北美肉毒桿菌毒素市場佔有率中佔據主導地位。

Merz Pharma GmbH & Co KGaA、AbbVie Inc、Ipsen SA、Evolus Inc、Aquavit、Revance Therapeutics Inc、Medytox Inc、Galderma SA、Hugel Inc 和蘭州生物製品研究所有限公司是在北美營運的一些領先公司肉毒毒素市場。

The botulinum toxins type A and B block vesicular acetylcholine released at neuromuscular and neurosecretory junctions, thereby delivering powerful therapeutic outcomes for treating patients requiring neurorehabilitation intervention. As per clinical reports, botulinum toxins have been proven to have therapeutic effects against headache, salivate, and hyperhidrosis, among others. Botulinum treatment can be adopted as an alternative to surgery. It appears to be a promising alternative to sphincterotomy in patients with chronic anal fissures. Patients suffering from a few autonomic disorders such as ptyalism or gustatory sweating, and hypersecretion of glands (a condition that often occurs after patients undergo surgeries involving parotid glands) respond well to botulinum toxins. Despite numerous advancements in the field of assisted reproductive technology, a significant number of patients still suffer from repeated implantation failure. Adequate endometrial growth plays a crucial role in embryo implantation and pregnancy continuation in an assisted reproductive procedure. For several years, botulinum toxins have been widely used in plastic and aesthetic surgeries; it has been revealed that botulinum toxins have a positive influence on the re-epithelialization of human keratinocytes and the angiogenesis of endothelial cells. Clinical results reveal that botulinum toxin administration facilitates the recovery of damaged structure and impaired function of the thin endometrium by increasing cellular proliferation and vessel formation, reducing collagen-accumulated lesions, and ultimately contributing to successful embryo implantation. Thus, the expanding therapeutic applications of botulinum toxins are likely to bring new botulinum toxins market trends in the coming years.

North America Botulinum Toxin Market Overview

The North America botulinum toxin market is segmented into the US, Canada, and Mexico. The market growth in North America can be mainly associated with the economically stable population and increasing numbers of nonsurgical or minimally invasive cosmetic procedures performed in the abovementioned countries. Reduction of facial wrinkles with botulinum toxin injections is the most performed cosmetic procedure in the US. It is one of the most common entry-level procedures for clinicians willing to incorporate aesthetic treatments into their practice. According to the International Society of Aesthetic Plastic Surgery (ISAPS), nearly 2.5 million botulinum toxin procedures were performed in the US in 2021. The treatment of frown lines and crow's feet approved by the US Food and Drug Administration- for cosmetic indications and horizontal forehead wrinkles provide predictable results, have few side effects, and high patient satisfaction. BOTOX Cosmetic/Vistabel by Allergan, Dysport/Azzalure by Galderma and Ipsen, Xeomin/Bocouture by Merz, and Jeuveau by Evolus (manufactured only by Daewoong for the US) are among the commercially available botulinum toxin products in the country. The US FDA has approved BOTOX Cosmetic for people from the age range of 18-65. According to the American Society for Aesthetic Plastic Surgery, botox injection is the fastest-growing procedure in the cosmetic industry. In August 2023, Daxxify (daxibotulinumtoxinA-lanm) was approved by the FDA as the first therapeutic indication to treat adult cervical dystonia. Cervical dystonia is characterized by uncontrollably occurring spasms or contractions in neck muscles, causing unusual movements, awkward posture, and head and neck pain. This condition affects approximately 60,000 Americans. The injection of botulinum toxin facilitates the relaxation of affected muscles in cervical dystonia patients, thereby reducing stiffness and spasms. However, the effect of the treatment slowly wears off, and thus, patients need frequent retreatments. Earlier, in July 2021, the FDA approved the label expansion of BOTOX Cosmetic of Allergan, an AbbVie company. Allergan has expanded BOTOX's applications to treat 8 new muscle conditions related to upper limb spasticity in adults.

North America Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)

North America Botulinum Toxin Market Segmentation

The North America botulinum toxin market is categorized into product, application, end user, and country.

Based on product, the North America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held the larger share of North America botulinum toxin market share in 2023.

In terms of application, the North America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held the larger share of North America botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow's feet, square jaw/ masseter, and others.

By end user, the North America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of North America botulinum toxin market in 2023.

Based on country, the North America botulinum toxin market is segmented into the US, Canada, and Mexico. The US dominated the North America botulinum toxin market share in 2023.

Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Aquavit, Revance Therapeutics Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd are some of the leading companies operating in the North America botulinum toxin market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Botulinum Toxin Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
- 4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
4.2 Market Restraints
- 4.2.1 Side Effects of Botulinum Toxin
4.3 Market Opportunities
- 4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
4.4 Future Trends
- 4.4.1 Expanding Therapeutic Applications
4.5 Impact of Drivers and Restraints:

5. Botulinum Toxin Market - North America Analysis

5.1 Overview
5.2 Botulinum Toxin Market Revenue (US$ Million), 2021-2031

6. North America Botulinum Toxin Market Analysis - by Product

6.1 Overview
6.2 Botulinum Toxin A
- 6.2.1 Overview
- 6.2.2 Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Botulinum Toxin B
- 6.3.1 Overview
- 6.3.2 Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

7. North America Botulinum Toxin Market Analysis - by Application

7.1 Overview
7.2 Medical
- 7.2.1 Overview
- 7.2.2 Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.2.2.1 North America Botulinum Toxin Market Breakdown, by Medical
7.3 Aesthetic
- 7.3.1 Overview
- 7.3.2 Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.3.2.1 North America Botulinum Toxin Market Breakdown, by Aesthetic

8. North America Botulinum Toxin Market Analysis - by End User

8.1 Overview
8.2 Specialty and Dermatology Clinics
- 8.2.1 Overview
- 8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Hospitals and Clinics
- 8.3.1 Overview
- 8.3.2 Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Botulinum Toxin Market - Country Analysis

9.1 North America: Botulinum Toxin Market
- 9.1.1 North America: Botulinum Toxin Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.1.3 United States: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.1.4 United States: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.1.4.1 United States: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.1.4.2 United States: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.1.5 United States: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.2 Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.2.3 Canada: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.2.4 Canada: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.2.4.1 Canada: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.2.4.2 Canada: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.2.5 Canada: Botulinum Toxin Market Breakdown, by End User
  - 9.1.1.3 Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.1.3.3 Mexico: Botulinum Toxin Market Breakdown, by Product
    - 9.1.1.3.4 Mexico: Botulinum Toxin Market Breakdown, by Application
    - 9.1.1.3.4.1 Mexico: Botulinum Toxin Market Breakdown, by Medical
    - 9.1.1.3.4.2 Mexico: Botulinum Toxin Market Breakdown, by Aesthetic
    - 9.1.1.3.5 Mexico: Botulinum Toxin Market Breakdown, by End User

10. Company Profiles

10.1 Merz Pharma GmbH & Co KGaA
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 AbbVie Inc
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Ipsen SA
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Evolus Inc
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Aquavit
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Revance Therapeutics Inc
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 Medytox Inc
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 Galderma SA
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
10.9 Hugel Inc
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments
10.10 Lanzhou Institute of Biological Products Co Ltd
- 10.10.1 Key Facts
- 10.10.2 Business Description
- 10.10.3 Products and Services
- 10.10.4 Financial Overview
- 10.10.5 SWOT Analysis
- 10.10.6 Key Developments

11. Appendix

11.1 About The Insight Partners

簡介目錄圖表

List Of Tables

Table 1. Botulinum Toxin Market Segmentation
Table 2. North America Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
Table 3. North America Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
Table 4. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 5. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 6. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
Table 7. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
Table 8. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 9. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 10. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 11. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
Table 12. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
Table 13. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 14. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 15. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 16. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
Table 17. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
Table 18. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 19. Glossary of Terms

List Of Figures

Figure 1. Botulinum Toxin Market Segmentation, by Country
Figure 2. Botulinum Toxin Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Botulinum Toxin Market Revenue (US$ Million), 2021-2031
Figure 5. Botulinum Toxin Market Share (%) - by Product (2023 and 2031)
Figure 6. Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Botulinum Toxin Market Share (%) - by Application (2023 and 2031)
Figure 9. Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. Botulinum Toxin Market Share (%) - by End User (2023 and 2031)
Figure 12. Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. North America: Botulinum Toxin Market, by Key Country - Revenue (2023) (US$ Million)
Figure 16. North America: Botulinum Toxin Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 17. United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)